Endogenous Cushing’s

We estimate that 25,000 patients in the US are currently diagnosed with endogenous Cushing’s syndrome, a rare endocrine disorder characterized by sustained elevated cortisol levels.*


Clinical Development in Endogenous Cushing’s Syndrome

RECORLEV® (levoketoconazole) is an investigational cortisol synthesis inhibitor, previously studied in SONICS, and currently being evaluated in LOGICS and OPTICS, phase 3 clinical trials for endogenous Cushing’s syndrome.

The safety and efficacy of RECORLEV (levoketoconazole) for treatment of endogenous Cushing’s syndrome have not been established.

Educational Segment on Endogenous Cushing’s Syndrome

Strongbridge Biopharma sponsored an educational segment about endogenous Cushing’s syndrome on The Balancing Act, “Behind the Mystery: Rare and Genetic Diseases.” The segment features Leslie Edwin, a patient with endogenous Cushing’s syndrome and Director of Support Groups for Cushing’s Support & Research Foundation, and Maria Fleseriu, MD, Professor/Director at the Pituitary Center at Oregon Health and Science University (OHSU). A broad range of topics related to Cushing’s syndrome are addressed within the segment, including symptoms, misdiagnosis, the importance of seeing an endocrinologist, screening methods, treatment options, and research efforts that are underway.

*Based on proprietary Strongbridge Biopharma plc market research.


  1. CSRF fact sheet. Cushing’s Support & Research Foundation website. http://csrf.net/understanding-cushings/fact-sheet/.
  2. Nieman LK, Biller BMK, Findling MHM, et al. Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.
  3. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology. 2010;92(suppl 1):65-70.
  4. Cushing’s disease. University of Virginia Health System: Neurosciences website. http://neurosciences.uvahealth.com/services/pituitary-tumors/conditions-treatments/cushings-disease.
  5. Greenman Y. Management of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(suppl 1):91-95.
  6. Cushing’s syndrome. NIH Publication No. 08-3007. July 2008. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases website. http://www.niddk.nih.gov/health-information/health-topics/endocrine/cushings-syndrome/Documents/Cushings_Syndrome_508.pdf.
  7. Bolanowski M, Halupczok J, Jawiarczyk-Przybylowska A. Pituitary disorders and osteoporosis. Int J Endocrinol. 2015:206853. Available at http://dx.doi.org/10.1155/2015/206853.

For accessibility-related questions, comments, or concerns about this digital property, please email [email protected] and we will reply to your message.

© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V18 05/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program